Kymera IPO Presentation Deck

IRAK4 Degradation In Vivo Active in Preclinical Mouse Psoriasis Model IL-1R/TLR driven Ability to inhibit topical skin thickening induced by imiquimod was measured in a mouse model of psoriasis • Orally dosed KT-474 inhibited thickening, a reflection of local and systemic inflammation, comparable to a topic corticosteroid after 2 or 4 days of dosing * Inhibition shown at doses achieving at least 60-70% IRAK4 knockdown in skin and spleen KYMERA & Ear thickness (µm) D % IRAK4 (Control) + SEM % IRAK4 (Control) + SEM 150 150 $% IMQ Skin Spleen

View entire presentation